Genmab A/S (NASDAQ:GMAB) Receives $45.20 Consensus Target Price from Analysts

Shares of Genmab A/S (NASDAQ:GMAB) have been given a consensus rating of “Moderate Buy” by the ten brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $45.20.

A number of research analysts recently weighed in on GMAB shares. Redburn Atlantic started coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating for the company. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Wednesday, January 8th. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th.

Genmab A/S Stock Down 2.0 %

GMAB opened at $20.80 on Tuesday. The company has a market capitalization of $13.76 billion, a PE ratio of 20.19, a price-to-earnings-growth ratio of 0.59 and a beta of 0.97. The firm has a 50-day simple moving average of $21.15 and a two-hundred day simple moving average of $24.07. Genmab A/S has a 52 week low of $19.85 and a 52 week high of $31.88.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The firm had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same period in the previous year, the company posted $0.47 earnings per share. As a group, sell-side analysts expect that Genmab A/S will post 1.28 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently modified their holdings of GMAB. Oppenheimer Asset Management Inc. lifted its position in shares of Genmab A/S by 26.3% during the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock worth $5,480,000 after purchasing an additional 45,376 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Genmab A/S by 94.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock valued at $636,000 after buying an additional 12,654 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after purchasing an additional 103,859 shares during the period. Verition Fund Management LLC bought a new stake in shares of Genmab A/S in the third quarter valued at about $709,000. Finally, HighTower Advisors LLC purchased a new stake in Genmab A/S in the third quarter worth about $273,000. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.